Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

4 April 2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that new therapies for the treatment of systemic lupus erythematosus (SLE), that can positively differentiate themselves from current therapies in their effect on disease activity, would be well received by physicians and would be poised to benefit from strong uptake.

Based on currently available clinical data and thought leader opinion, the emerging therapies epratuzumab (Immunomedics [Nasdaq: IMMU] and UCB [Euronext Brussels: UCB]) and Lupuzor (ImmuPharma’s [LSE:IMM] forigerimod, P140, CEP-33457) have the potential to offer improvements over IV belimumab (GlaxoSmithKline’s [LSE: GSK] Benlysta) in reducing disease activity. Thought leaders perceive belimumab to offer only modest efficacy benefits in patients who are refractory to conventional immunosuppressants.

Blisibimod also shows potential

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK